NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML),1 inotuzumab in non-Hodgkin lymphoma (NHL),2 as well as the first presentation of clinical data for PF-04449913,3 which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.4 In addition, ongoing investigator-initiated research on gemtuzumab ozogamicin (Mylotarg) will be presented in the plenary session.5 These data will be presented at the upcoming 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, December 10-13.
